ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024

Oric Pharmaceuticals, Inc.

ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.
Focus shifts to three single-agent Phase 1b programs: ORIC-533 (multiple myeloma), ORIC-114 (EGFR/HER2), ORIC-944 (prostate); initial data expected 1H 2023.
Cash and investments $280.4M as of Dec 31, 2021; cash runway extended into second half of 2024 following ORIC-101 discontinuation.
Q4 2021 R&D expenses $16.7M (vs $12.1M Q4 2020); G&A $6.1M (vs $4.3M); increases driven by program advancement and public company costs.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.